Cargando…

The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)

The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation....

Descripción completa

Detalles Bibliográficos
Autores principales: Podoly, Erez, Shalev, Deborah E., Shenhar-Tsarfaty, Shani, Bennett, Estelle R., Ben Assayag, Einor, Wilgus, Harvey, Livnah, Oded, Soreq, Hermona
Formato: Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719355/
https://www.ncbi.nlm.nih.gov/pubmed/19383604
http://dx.doi.org/10.1074/jbc.M109.004952
_version_ 1782170067739344896
author Podoly, Erez
Shalev, Deborah E.
Shenhar-Tsarfaty, Shani
Bennett, Estelle R.
Ben Assayag, Einor
Wilgus, Harvey
Livnah, Oded
Soreq, Hermona
author_facet Podoly, Erez
Shalev, Deborah E.
Shenhar-Tsarfaty, Shani
Bennett, Estelle R.
Ben Assayag, Einor
Wilgus, Harvey
Livnah, Oded
Soreq, Hermona
author_sort Podoly, Erez
collection PubMed
description The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the “usual” BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing Aβ oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed β-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from Aβ neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes.
format Text
id pubmed-2719355
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher American Society for Biochemistry and Molecular Biology
record_format MEDLINE/PubMed
spelling pubmed-27193552009-08-14 The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦) Podoly, Erez Shalev, Deborah E. Shenhar-Tsarfaty, Shani Bennett, Estelle R. Ben Assayag, Einor Wilgus, Harvey Livnah, Oded Soreq, Hermona J Biol Chem Genomics, Proteomics, and Bioinformatics The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate β-amyloid (Aβ) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the “usual” BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing Aβ oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed β-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from Aβ neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes. American Society for Biochemistry and Molecular Biology 2009-06-19 2009-04-21 /pmc/articles/PMC2719355/ /pubmed/19383604 http://dx.doi.org/10.1074/jbc.M109.004952 Text en © 2009 by The American Society for Biochemistry and Molecular Biology, Inc. Author's Choice—Final version full access. Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) applies to Author Choice Articles
spellingShingle Genomics, Proteomics, and Bioinformatics
Podoly, Erez
Shalev, Deborah E.
Shenhar-Tsarfaty, Shani
Bennett, Estelle R.
Ben Assayag, Einor
Wilgus, Harvey
Livnah, Oded
Soreq, Hermona
The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title_full The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title_fullStr The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title_full_unstemmed The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title_short The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology(♦)
title_sort butyrylcholinesterase k variant confers structurally derived risks for alzheimer pathology(♦)
topic Genomics, Proteomics, and Bioinformatics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2719355/
https://www.ncbi.nlm.nih.gov/pubmed/19383604
http://dx.doi.org/10.1074/jbc.M109.004952
work_keys_str_mv AT podolyerez thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT shalevdeborahe thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT shenhartsarfatyshani thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT bennettesteller thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT benassayageinor thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT wilgusharvey thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT livnahoded thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT soreqhermona thebutyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT podolyerez butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT shalevdeborahe butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT shenhartsarfatyshani butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT bennettesteller butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT benassayageinor butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT wilgusharvey butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT livnahoded butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology
AT soreqhermona butyrylcholinesterasekvariantconfersstructurallyderivedrisksforalzheimerpathology